Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02687932
Other study ID # 2015-0938
Secondary ID
Status Completed
Phase Phase 4
First received February 17, 2016
Last updated January 8, 2018
Start date March 2016
Est. completion date January 2, 2018

Study information

Verified date January 2018
Source Asan Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Functional MR is caused by adverse left ventricular remodeling after myocardial injury and associated with an increased incidence of heart failure and death. Because secondary functional MR usually develops as a result of LV dysfunction, diuretics, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and aldosterone antagonists are given to patients with functional MR in line with the guidelines in the management of heart failure. However, functional MR appears to remain common despite use of these drugs and current medical treatment is usually insufficient for reducing MR or reversing the adverse LV remodeling. As LCZ696 is a dual-acting inhibitor of the renin-angiotensin-aldosterone system (RAAS) and neutral endopeptidase (NEP), LCZ696 has greater hemodynamic and neurohormonal effects than ARB alone. Investigators try to examine the hypothesis that LCZ696 is superior to ARB alone in improving functional MR in patients with LV dysfunction and functional MR.


Description:

Functional ischemic mitral regurgitation (MR) has been reported to occur in up to 40% of patients after myocardial infarction, and the prevalence of functional MR is likely to increase with an aging population and improved survival rates for myocardial infarction. The presence of functional MR is associated with an increased incidence of heart failure and death, and patients with significant functional MR incur about a two-fold increase in the risk of mortality and about a four-fold increase in the risk of heart failure. Functional MR is caused by adverse left ventricular remodeling after myocardial injury with enlargement of the left ventricle (LV), apical and lateral displacement of papillary muscles, leaflet tethering and reduced closing forces. The leaflets are normal in secondary functional MR and the treatment is considerably different between functional and primary MR. Surgery is the only definitive therapy for primary severe MR and primary MR can usually be cured by surgical valve repair. However, surgical indications are unclear in severe functional MR, because outcomes after surgery for functional MR remain suboptimum. Operative mortality, long-term mortality and heart failure rates are still high in patients with severe functional MR despite surgical improvements. According to the current guidelines, mitral valve surgery may be considered only for severely symptomatic patients with severe secondary functional MR who have persistent symptoms despite optimal medical therapy for heart failure.

Because secondary functional MR usually develops as a result of LV dysfunction, diuretics, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and aldosterone antagonists are given to patients with functional MR in line with the guidelines in the management of heart failure. However, functional MR appears to remain common despite use of these drugs and current medical treatment is usually insufficient for reducing MR or reversing the adverse LV remodeling. Persistence of functional MR due to the insufficient effectiveness of current medical treatment significantly increases morbidity and mortality, and compared with surgical or percutaneous revascularization, significantly higher mortality was observed in patients managed with medical therapy.

Quantitative assessment of MR is strongly recommended in the guidelines and the regurgitant volume and the effective regurgitant orifice area (EROA) of MR can be measured accurately and reproducibly by Doppler echocardiography. The EROA of MR has an important prognostic value in primary and secondary functional MR. Because functional MR carries an adverse prognosis with a graded relationship between MR severity and reduced survival, therapies that induce beneficial reverse remodeling of the LV and reduce MR, may improve survival. ACE inhibitors and ARBs could partially attenuate LV dilatation and remodeling after myocardial injury, but there are no published data from prospective trials regarding whether attenuation of remodeling by ACE inhibitors or ARBs reduces functional MR.

LCZ696 is a dual-acting inhibitor of the renin-angiotensin-aldosterone system (RAAS) and neutral endopeptidase (NEP). As LCZ696 offers the therapeutic advantages of concomitantly blocking both RAAS and NEP, LCZ696 was more effective in reducing the risk of death from cardiovascular causes or hospitalization for heart failure in patients with chronic heart failure than ACE inhibitor. Because NEP is involved in the metabolism of a number of vasoactive peptides such as natriuretic peptides, NEP inhibitor has vasodilating effects, facilitates sodium excretion and has profound effects on LV remodeling. Trials of hypertension and heart failure with a preserved ejection fraction also showed that LCZ696 had greater hemodynamic and neurohormonal effects than ARB alone. To date, there has been no proven pharmacological therapy to improve functional MR, and the development of medical therapy should be at the forefront of research considering the limited role of surgery in managing functional MR. Investigators hypothesize that LCZ696 is superior to ARB alone in improving functional MR in patients with LV dysfunction and functional MR via synergistic effects of NEP and RAAS inhibition on LV remodeling, and try to examine this hypothesis in a multicenter, double-blind, randomized comparison study using echocardiography.


Recruitment information / eligibility

Status Completed
Enrollment 118
Est. completion date January 2, 2018
Est. primary completion date January 2, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Patients must agree to the study protocol and provide written informed consent

2. Outpatients = 20 years of age, male or female

3. Patients with secondary functional MR (stage B and C) and LV dysfunction

- Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent

- Normal mitral valve leaflets and chords

- Regional or global wall motion abnormalities with mild or severe tethering of leaflet

- ERO > 0.10 cm2

- 25% < LV ejection fraction < 50%

4. Dyspnea of NYHA functional class II or III

5. Patients must be on stable, optimized dose of an ACE inhibitors or ARBs for at least 4 weeks prior to study entry

Exclusion Criteria:

1. History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, ARBs, or NEP inhibitors as well as known or suspected contraindications to the study drug

2. Known history of angioedema

3. Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles

4. Current acute decompensated heart failure or dyspnea of NYHA functional class IV

5. Medical history of hospitalization within 6 weeks

6. Symptomatic hypotension and/or a SBP < 100 mmHg at screening

7. Estimated GFR < 30 mL/min/1.73m2

8. Serum potassium > 5 mmol/L at screening

9. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt

10. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months

11. Planned coronary revascularization or mitral valve intervention within 1 year

12. Heart transplantation or implantation of cardiac resynchronization therapy

13. History of severe pulmonary disease

14. Significant aortic valve disease

15. Primary aldosteronism

16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method

17. Pregnant or nursing (lactating) women

18. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

Study Design


Intervention

Drug:
LCZ696

Valsartan


Locations

Country Name City State
Korea, Republic of Inha University Hospital Incheon
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Yonsei University Medical Center Seoul

Sponsors (2)

Lead Sponsor Collaborator
Asan Medical Center Novartis

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation from baseline to 12 months follow-up 12 months
Secondary Change of regurgitant volume from baseline to 12 months follow-up 12 months
Secondary Change of left ventricular end-systolic volume from baseline to 12 months follow-up 12 months
Secondary Change of left ventricular end-diastolic volume from baseline to 12 months follow-up 12 months
Secondary Change of incomplete mitral leaflet closure area from baseline to 12 months follow-up 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03962023 - Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)
Withdrawn NCT02624960 - Safety and Performance of the AccuCinch® System N/A
Terminated NCT02428010 - Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study N/A
Active, not recruiting NCT01533883 - Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair N/A
Unknown status NCT01201070 - Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Phase 4
Terminated NCT00700947 - Using Beta Blockers to Treat Mitral Regurgitation Phase 1
Completed NCT04351984 - Transcatheter Mitral Valvuloplasty Pilot Study
Completed NCT04231331 - Ertugliflozin for Functional Mitral Regurgitation Phase 3
Completed NCT05742789 - Effect of Anesthetics on Troponin I and ะก-reactive Protein Phase 1
Recruiting NCT02803957 - Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair N/A
Recruiting NCT04153292 - The ENCIRCLE Trial N/A
Completed NCT02607527 - Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System N/A
Active, not recruiting NCT03066050 - Long Term Follow Up for CTSN Mitral Valve Repair Studies
Active, not recruiting NCT04443218 - Edwards PASCAL Transcatheter Valve Repair System Registry
Enrolling by invitation NCT04067635 - Primary Mitral Regurgitation Repair
Completed NCT01966146 - Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI N/A
Recruiting NCT01368575 - Surgical Treatment of Ischemic Mitral Regurgitation Phase 4
Completed NCT00001314 - Investigation of Heart Function in Patients With Heart Valve Defects N/A
Terminated NCT03285724 - Safety and Performance Study of the Harpoon Mitral Valve Repair System N/A
Withdrawn NCT04709042 - Acquisition of Objective Data During Transapical Neochordae Implantation N/A